Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.

Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Von Hoff, D. D., Goodwin, A. L., Garcia, L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062801/
https://www.ncbi.nlm.nih.gov/pubmed/9717985
_version_ 1782137224048934912
author Von Hoff, D. D.
Goodwin, A. L.
Garcia, L.
author_facet Von Hoff, D. D.
Goodwin, A. L.
Garcia, L.
author_sort Von Hoff, D. D.
collection PubMed
description Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been shown to provide clinical benefit for patients (decreased pain and improved performance status) as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease.
format Text
id pubmed-2062801
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20628012009-09-10 Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team. Von Hoff, D. D. Goodwin, A. L. Garcia, L. Br J Cancer Research Article Pancreatic cancer is a major cause of death from cancer in both men and women in the USA and Europe. The disease causes pain and has a significant impact on the performance status of the patient. In a randomized trial vs 5-fluorouracil, the novel nucleoside analogue gemcitabine (GEMZAR) has been shown to provide clinical benefit for patients (decreased pain and improved performance status) as well as to improve the time to tumour progression and survival for patients with the disease. There are also other new agents that are presented in this discussion, such as the multi-targeted antifolate MTA, capecitabine and the ONYX-015 adenovirus, which replicates in, and kills, only p53-abnormal cells, which have the potential to have an impact on this terrible disease. Nature Publishing Group|1 1998 /pmc/articles/PMC2062801/ /pubmed/9717985 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Von Hoff, D. D.
Goodwin, A. L.
Garcia, L.
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
title Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
title_full Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
title_fullStr Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
title_full_unstemmed Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
title_short Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
title_sort advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. the san antonio drug development team.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062801/
https://www.ncbi.nlm.nih.gov/pubmed/9717985
work_keys_str_mv AT vonhoffdd advancesinthetreatmentofpatientswithpancreaticcancerimprovementinsymptomsandsurvivaltimethesanantoniodrugdevelopmentteam
AT goodwinal advancesinthetreatmentofpatientswithpancreaticcancerimprovementinsymptomsandsurvivaltimethesanantoniodrugdevelopmentteam
AT garcial advancesinthetreatmentofpatientswithpancreaticcancerimprovementinsymptomsandsurvivaltimethesanantoniodrugdevelopmentteam

Ejemplares similares